



In vivo Toxicity Testing

Justin Conley

Center for Public Health and Environmental Assessment
Office of Research and Development

Executive Meeting | Board of Scientific Counselors
September 29-30, 2021

The views expressed in this presentation are those of the author(s) and do not necessarily represent the views or policies of the U.S. Environmental Protection Agency.



Goals

- **In vivo developmental, liver, thyroid, or immune endpoints are the basis for essentially all risk assessment points-of-departure**
- **Unstudied PFAS have been detected in human serum and/or drinking water**
- **Monitoring studies consistently demonstrate co-exposure to multiple PFAS**
- **ORD research filling data gaps to:**
 - **Generate toxicity data for unstudied PFAS with human exposure**
 - **Characterize Adverse Outcome Pathways associated with exposure during pregnancy**
 - **Investigate cumulative effects of co-exposure to multiple PFAS**
 - **Evaluate PFAS estrogenicity in vivo**
 - **Evaluate how changes in thyroid hormones relate to functional deficits**
- **Results will advance PFAS toxicology, strengthen scientific basis of state/federal PFAS risk assessments, and provide data to inform PFAS regulatory actions**



- **ORD in vivo research largely focused on oral exposure to PFAS during pregnancy**
- **Hypothesis-driven study designs with measurement of critical key events and adverse outcomes in maternal and F1 animals**
 - **Organ weights, viability, clinical chemistry**
 - **Thyroid hormone concentrations**
 - **Test compound concentrations**
 - **Tissue-specific gene expression**
 - **Histopathology**
 - **Studies largely conducted in dose response across a range of legacy and emerging PFAS**
- **Novel data-rich approaches included such as RNA-Seq, targeted metabolomics, and multiple confocal microscopy**

• Publications to-date:


- Conley et al. 2019. Adverse maternal, fetal, and postnatal effects of hexafluoropropylene oxide dimer acid (GenX) from oral gestational exposure in Sprague-Dawley rats. doi: 10.1289/EHP4372
- Conley et al. 2021. Hexafluoropropylene oxide dimer acid (HFPO-DA or GenX) alters maternal and fetal glucose and lipid metabolism and produces neonatal mortality, low birthweight, and hepatomegaly in the Sprague-Dawley rat. doi: 10.1016/j.envint.2020.106204.
- Gilbert et al., 2021. Thyroid Disruptors: Extrathyroidal Sites of Chemical Action and Neurodevelopmental Outcome-An Examination Using Triclosan and Perfluorohexane Sulfonate. doi: 10.1093/toxsci/kfab080.

• Completed and on-going studies with anticipated publications

- RNA-Seq of the developing rat brain and liver following maternal PFHxS exposure
- Developmental toxicity of Nafion byproduct 2, PFMOAA, and two PFAS mixture studies
- Uterotrophic studies of several ER active PFAS



Conley et al., 2021 doi: 10.1016/j.envint.2020.106204



Gilbert et al., 2021 doi: 10.1093/toxsci/kfab080



Contributors

Justin Conley (ORD/CPHEA)

Aaron Dixon (ORD/CPHEA)

Nicki Evans (ORD/CPHEA)

Aimen Farraj (ORD/CPHEA)

Jermaine Ford (ORD/CCTE)

Mary Gilbert (ORD/CPHEA)

Earl Gray (ORD/CPHEA)

Rachel Grindstaff (ORD/CPHEA)

Susan Hester (ORD/CCTE)

Erin Hines (ORD/CPHEA)

Christy Lambright (ORD/CPHEA)

Denise MacMillan (ORD/CCTE)

James McCord (ORD/CEMM)

Elizabeth Medlock Kakaley (ORD/CPHEA)

Katie O'Shaughnessy (ORD/CPHEA)

Mark Strynar (ORD/CEMM)

Leah Wehmas (ORD/CCTE)

Supported by Chemical Safety for Sustainability (CSS)